1.9.1 Drugs affecting biliary composition and flow

Ursodeoxycholic Acid

• Tablets 150mg, 250mg, 300mg (£18.00 = 60 x 250mg tablets)
• Oral suspension sugar free 250mg in 5ml (£26.98 = 250ml)

Indications and dose

• Dissolution of gallstones
  • 8–12mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
• Primary biliary cirrhosis
  • 12–16mg/kg daily in 3 divided doses for 3 months, then 12–16mg/kg once daily at bedtime

Obeticholic acid

• Tablets 5mg, 10mg

Notes

1. NICE TA443 Obeticholic acid for treating primary biliary cholangitis (April 2017) (NHS England Commissioned)

Odevixibat

• Hard capsules 200 micrograms, 400 micrograms, 600 micrograms, 1,200 micrograms

Notes

1. NICE HST17: Odevixibat (Bylvay) is recommended, within its marketing authorisation, as an option for treating progressive familial intrahepatic cholestasis (PFIC) in people 6 months and older (February 2022). It is recommended only if the company provides odevixibat according to the commercial arrangement.

 

Home > Formulary > Chapters > 1. Gastrointestinal > 1.9 Drugs affecting intestinal secretions > 1.9.1 Drugs affecting biliary composition and flow

 

• First line
• Second line
• Specialist
• Hospital